Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12600052 | 0.92 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL12600038 | 0.92 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL12600169 | 0.81 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL12600109 | 0.80 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL12600157 | 0.79 | FFAR1 (0.39) | ALDH1A1SMN1; SMN2KDM4EHPGDRAB9A | |
| SCHEMBL12600131 | 0.79 | KDM4E (0.43) | ALDH1A1SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL22397218 | 0.78 | DRD2 (0.35) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL2818376 | 0.78 | TAS1R3 (0.39) | SMN1; SMN2MAPTKMT2AMEN1KDM4E | |
| SCHEMBL12600150 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL12600129 | 0.76 | CYP2D6 (0.35) | ALDH1A1KDM4EROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935827-B2 | Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto esters | BAYER SCHERING PHARMA AG (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20100248313-A1 | NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS | BAYER SCHERING PHARMA AG (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7626035-B2 | Ethyl 2-(benzothiazol-2-yl),2-oxo-acetate; useful in the synthesis of epothilonederivatives; antitumor,-carcinogenic agents; high chemical purity, optical purity,in very good yields and allows an industrial-scale production | BAYER SCHERING PHARMA AG (DE) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100248313-A1 | NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS | CYP8B1, HSD17B7, CYP51A1 | ALDH1A1 286/4885SMN1; SMN2 4806/4885MAPT 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.